UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000040910
Receipt number R000045680
Scientific Title Establishment of a system for treatment selection in patients aged 80 years or older with early gastric cancer and superficial esophageal cancer.
Date of disclosure of the study information 2020/07/01
Last modified on 2023/07/28 06:20:33

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Establishment of a system for treatment selection in patients aged 80 years or older with early gastric cancer and superficial esophageal cancer.

Acronym

E-STAGE TRIAL

Scientific Title

Establishment of a system for treatment selection in patients aged 80 years or older with early gastric cancer and superficial esophageal cancer.

Scientific Title:Acronym

E-STAGE TRIAL

Region

Japan


Condition

Condition

superficial esophageal cancer and early gastric cancer

Classification by specialty

Gastroenterology Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To establish a system for treatment selection including geriatric assessment for patients aged 80 years or older with superficial esophageal cancer and early gastric cancer

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Factors associated with 3-year mortality in patients with superficial esophageal cancer.
Factors associated with 3-year mortality in patients with early gastric cancer.

Key secondary outcomes

1) Overall survival in patients with superficial esophageal cancer and early gastric cancer.
2) Factors associated with 3-year mortality in upper gastrointestinal cancer (superficial esophageal cancer/early gastric cancer).
3) The decrease rate of QOL (symptom score) at 3 years after the treatment compared with the time of registration and factors associated with the lower QOL (symptom score) in patients with superficial esophageal cancer and early gastric cancer
4) Factors associated with lower QOL (symptom score) at 3 years after the treatment compared with the time of registration in patients with upper gastrointestinal cancer (superficial esophageal cancer/early gastric cancer).
5) Validation of the prediction model for 3-year overall survival in patients with early gastric cancer.
6) Validation of the prediction model for lower QOL (symptom score) at 3 years after the treatment in patients with early gastric cancer.
7) Difference between the prediction model for 3-year overall survival by artificial intelligence and that by statistical analysis.
8) Difference between the prediction model for lower QOL (symptom score) at 3 years after the treatment by artificial intelligence and statistical analysis.
9) Progression rate of cT stage of the lesions without treatment in patients with superficial esophageal cancer and early gastric cancer.
10) The incidence rate of metachronous cancers after endoscopic treatment in patients with superficial esophageal cancer and early gastric cancer
11) The 3-year skeletal muscle mass reduction rate and factors associated with the skeletal muscle mass reduction in patients with curability C-2 after endoscopic resection for early gastric cancer.
12) Validation of the eCura system in patients with curability C-2 after endoscopic resection for early gastric cancer.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

80 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Patients diagnosed as esophageal or gastric tumor by endoscopy.
(2) Patients diagnosed or suspected as carcinoma by biopsy or resected specimen.
(3) Patients with esophageal/gastric cancers that confined to submucosa in clinical diagnosis.
(4) Patients with 80 years or older.
(5) Patients with written informed consent for study participation.

Key exclusion criteria

(1) Patients who refuse to participate in the study.
(2) Patients with esophageal/gastric cancers invading into the muscularis propria in the resected specimen.
(3) Patients who are regarded as inappropriate by the investigator.

Target sample size

1100


Research contact person

Name of lead principal investigator

1st name Waku
Middle name
Last name Hatta

Organization

Tohoku University Graduate School of Medicine

Division name

Division of Gastroenterology

Zip code

980-8574

Address

1-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan

TEL

022-717-7171

Email

waku-style@festa.ocn.ne.jp


Public contact

Name of contact person

1st name Akira
Middle name
Last name Maekawa

Organization

Osaka International Cancer Institute

Division name

Department of Gastrointestinal Oncology

Zip code

541-8567

Address

3-1-69, Otemae, Chuo-ku, Osaka. Osaka, Japan

TEL

06-6945-1181

Homepage URL


Email

makira1980@gmail.com


Sponsor or person

Institute

Tohoku University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Japan Gastroenterological Endoscopy Society

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

the Ethics Committee of Tohoku University Hospital

Address

1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan

Tel

022-728-4105

Email

ec@rinri.hosp.tohoku.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 07 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2020 Year 04 Month 03 Day

Date of IRB

2020 Year 04 Month 09 Day

Anticipated trial start date

2020 Year 07 Month 01 Day

Last follow-up date

2025 Year 02 Month 28 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

In this study, we perform geriatric assessment at the time of registration for patients aged 80 years or older with superficial esophageal cancer and early gastric cancer. We evaluate the several factors associated with 3-year mortality and lower QOL (symptom score) and validate the prediction model for 3-year overall survival and lower QOL.
Based on the results, we aim to establish a system for treatment selection including geriatric assessment for patients aged 80 years or older with superficial esophageal cancer and early gastric cancer.


Management information

Registered date

2020 Year 06 Month 26 Day

Last modified on

2023 Year 07 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045680


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name